Friday, November 23, 2018
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced in the district of Fengxian in Shanghai.
The new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists.
"The commencement of this new biologics center will further expand WuXi Biologics' unparalleled capacities and we are glad to witness its construction today. WuXi Biologics is committed to developing and manufacturing biologics more cost effectively as well as to providing a robust supply chain network for our global partners to benefit patients worldwide," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.